Table 3 Selective clinical trials of drugs targeting bone microenvironment
From: Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Drug | Target | Condition | Status | Phase | NCT identifier |
|---|---|---|---|---|---|
Radium-223 | Calcium-mimetic α-emitting | Bone-metastatic CRPC | Completed | 3 | NCT00699751 |
Radium-223 | Calcium mimetic α-emitting | Bone-metastatic CRPC | Completed | 3 | NCT01618370 |
Radium-223 | Calcium mimetic α-emitting | Bone-metastatic CRPC | Completed | 3 | NCT01810770 |
Radium-223 | Calcium mimetic α-emitting | Bone-metastatic CRPC | Recruiting | 3 | NCT03432949 |
Strontium-89 | Calcium mimetic β-emitting | Bone-metastatic CRPC | Completed | 3 | NCT00002503 |
Samarium-153 | Calcium mimetic β-emitting | Bone-metastatic CRPC | Completed | 3 | NCT00365105 |
Zoledronic acid | FDPS | Bone-metastatic CRPC | Completed | 3 | NCT00242567 |
Zoledronic acid | FDPS | Bone-metastatic CRPC | Completed | 3 | NCT00079001 |
Zoledronic acid | FDPS | Bone-metastatic CRPC | Completed | 3 | NCT00321620 |
Zoledronic acid | FDPS | Bone-metastatic CRPC | Completed | 4 | NCT00242554 |
Clodronic acid | FDPS | PCa | Completed | Unknown | NCT01198457 |
Risedronic acid | FDPS | PCa | Completed | 3 | NCT00426777 |
Alendronic acid | FDPS | Metastatic PCa | Terminated | 2 | NCT00019695 |
Ibandronic acid | FDPS | Metastatic PCa | Completed | 3 | NCT00082927 |
Denosumab | RANKL | CRPC | Completed | 3 | NCT01824342 |
Denosumab | RANKL | CRPC | Completed | 3 | NCT00286091 |
Denosumab | RANKL | CRPC | Completed | 3 | NCT00838201 |
Denosumab | RANKL | PCa | Completed | 3 | NCT00925600 |
Mipsagargin | SERCA | Metastatic PCa | Withdrawn | 2 | NCT01734681 |
SOR-C13 | TRPV6 | Advanced cancers | Recruiting | 1 | NCT03784677 |
